A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate

被引:28
|
作者
Serra-Guillen, C. [1 ]
Nagore, E. [1 ]
Hueso, L. [1 ]
Llombart, B. [1 ]
Requena, C. [1 ]
Sanmartin, O. [1 ]
Botella-Estrada, R. [1 ]
Guillen, C. [1 ]
机构
[1] Inst Valenciano Oncol, Dept Dermatol, Valencia 46009, Spain
关键词
SQUAMOUS-CELL CARCINOMA; FOLLOW-UP; CRYOTHERAPY; METAANALYSIS; MULTICENTER; PAIN; 5-FLUOROURACIL; EXTREMITIES; MANAGEMENT; EFFICACY;
D O I
10.1111/j.1365-2133.2010.10098.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P>Background Photodynamic therapy (PDT) and imiquimod are two excellent treatments for actinic keratosis but are often not well tolerated by patients. Objectives To ascertain which treatment is better tolerated and which produces greater patient satisfaction. A secondary objective was to determine the factors related to the patient's tolerance to each treatment. Methods Patients with at least five actinic keratosis lesions on the face and scalp were selected. The patients were randomized to receive treatment with PDT with methyl aminolaevulinate or treatment with imiquimod. Tolerance, satisfaction and predisposition to repeat the treatment were evaluated. Results Most patients exhibited good or acceptable tolerance to both PDT and imiquimod treatment. There was a higher percentage of patients treated with PDT (93%) who were very satisfied compared with imiquimod (62%) (P = 0 center dot 004). Most patients treated with either one of the two options would repeat the same treatment. No significant relationship was found between age, sex, working time exposed to the sun, phototype and hair colour and the tolerance to both treatments. Conclusions Both PDT and imiquimod are treatments that are generally well tolerated. While both treatments provide a high level of satisfaction, PDT appears to be slightly superior in this regard.
引用
收藏
页码:429 / 433
页数:5
相关论文
共 49 条
  • [1] Comparative study of imiquimod 3.75% vs. photodynamic therapy for actinic keratosis of the scalp
    Cortelazzi, Chiara
    Odorici, Giulia
    Castagnetti, Elisa
    Pellacani, Giovanni
    Di Nuzzo, Sergio
    PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2021, 37 (05) : 404 - 409
  • [2] A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp
    Zane, C.
    Facchinetti, E.
    Rossi, M. T.
    Specchia, C.
    Calzavara-Pinton, P. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (05) : 1143 - 1150
  • [3] A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: Clinical and histologic outcomes
    Serra-Guillen, Carlos
    Nagore, Eduardo
    Hueso, Luis
    Traves, Victor
    Messeguer, Francesc
    Sanmartin, Onofre
    Llombart, Beatriz
    Requena, Celia
    Botella-Estrada, Rafael
    Guillen, Carlos
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : E131 - E137
  • [4] Effectiveness and safety of 0•5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial
    Miola, A. C.
    Ferreira, E. R.
    Lima, T. R. R.
    Schmitt, J. V.
    Abbade, L. P. F.
    Miot, H. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (05) : 1081 - 1087
  • [5] Comparative Efficacy and Tolerability of Imiquimod 3.75% Cream vs 5-Fluorouracil 4% cream in the Treatment of Actinic Keratosis: A Split-Face Study
    Ariasi, Cesare
    Romano, Carola
    Tomasi, Cesare
    Licata, Gaetano
    Geat, Davide
    Calzavara-Pinton, Piergiacomo
    Arisi, Mariachiara
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2025, 15 (01):
  • [6] Comparative study of trichloroacetic acid vs. photodynamic therapy with topical 5-aminolevulinic acid for actinic keratosis of the scalp
    Di Nuzzo, Sergio
    Cortelazzi, Chiara
    Boccaletti, Valeria
    Zucchi, Alfredo
    Conti, Maria Luisa
    Montanari, Paola
    Feliciani, Claudio
    Fabrizi, Giuseppe
    Pagliarello, Calogero
    PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2015, 31 (05) : 233 - 238
  • [7] Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo
    Dirschka, T.
    Radny, P.
    Dominicus, R.
    Mensing, H.
    Bruening, H.
    Jenne, L.
    Karl, L.
    Sebastian, M.
    Oster-Schmidt, C.
    Kloevekorn, W.
    Reinhold, U.
    Tanner, M.
    Groene, D.
    Deichmann, M.
    Simon, M.
    Huebinger, F.
    Hofbauer, G.
    Kraehn-Senftleben, G.
    Borrosch, F.
    Reich, K.
    Berking, C.
    Wolf, P.
    Lehmann, P.
    Moers-Carpi, M.
    Hoenigsmann, H.
    Wernicke-Panten, K.
    Helwig, C.
    Foguet, M.
    Schmitz, B.
    Luebbert, H.
    Szeimies, R. -M.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (01) : 137 - 146
  • [8] Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases
    Held, Laura
    Eigentler, Thomas Kurt
    Leiter, Ulrike
    Garbe, Claus
    Berneburg, Mark-Juergen
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [9] A Randomized Split-Face Clinical Trial of Photodynamic Therapy with Methyl Aminolevulinate versus Ingenol Mebutate Gel for the Treatment of Multiple Actinic Keratoses of the Face and Scalp
    Zane, Cristina
    Fabiano, Antonella
    Arisi, Mariachiara
    Calzavara-Pinton, Piergiacomo
    DERMATOLOGY, 2016, 232 (04) : 472 - 477
  • [10] A study of topical methyl-aminolaevulinate red-light photodynamic therapy in the treatment of actinic keratosis in Chinese patients: a Singaporean experience
    Oh, C. C.
    Theng, T. S. C.
    Chong, W. S.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2015, 40 (05) : 502 - 506